Anyone can catch and spread flu. It’s an infectious disease that does more damage than most people realize. It can lead to severe complications, increasing the risk of heart attack and pneumonia.

Flu impacts people’s lives and puts a considerable strain on already stretched health systems during the winter season. Vaccines are the best public health tool available to prevent flu and its serious complications. 

But not all flu vaccines are the same. We believe we must protect beyond the influenza infection to help reduce the risks of its severe complications, which too often bring people to hospital.

Facts about Flu

The Real Burden of Flu

  • Flu can cause a 10X increased risk of heart attack within the week following a flu infection2
  • Flu can increase your risk of stroke and pneumonia X82,5

Protection Beyond Flu

“With our influenza vaccines, we seek to not only prevent influenza but also protect against its severe complications like heart attack and pneumonia. We aim to ensure these vaccines, supported by a high level of evidence, are available to protect as many people as possible each flu season.”

Sandrine Samson, PhD
Global Medical Affairs Influenza, Sanofi

Innovation for Flu and Beyond

We are pursuing next generation influenza vaccines with multiple vaccine technologies to develop and bring forward tomorrow’s vaccines to people around the world as fast as possible.

That means not only using mRNA or protein-based technologies, but also novel methods of antigen selection in order to induce broader protection.

We are currently innovating in our existing different technologies including egg-based flu vaccines, recombinant proteins, mRNA to develop and deliver vaccines that can protect as many people as possible against flu and its complications.

More about Flu Vaccines

How managing COVID-19 has made predicting influenza even more complex

Upshot #9 - On World Heart Day, It's Time for a Flu Shot

Pictures of flu vaccines manufacturing, R&D, vaccination


  1. WHO. Influenza (seasonal) Fact Sheet. Available at: Accessed March 2022
  2. Warren-Gash C, et al. Eur respir J. 2018 Mar 29;51(3):1701794. 
  3. Andrew MK et al. J Am Geriatr Soc. 2021 Mar;69(3):696-703.
  4. Samson et al. J Diabetes Sci Technol. 2019 Nov 20:1932296819883340
  5. Kubale J, et al. Clin Infect Dis. 2021 Dec 6;73(11):e4288-e4295
  6. Chang LJ, et al. (2019). Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Adults ≥65 Years of Age: A Phase 3 Randomized Clinical Trial. Vaccine. 2019 Sep 16;37(39):5825-5834. doi: 10.1016/j.vaccine.2019.08.016
  7. MacIntyre CR, et al. Heart 2016;102:1953–1956. Available at: Accessed March 2022
  8. WHO - Coadministration of seasonal inactivated influenza and COVID-19 vaccines. Available at: Accessed March 2022
  9. Izikson R. et al. (2022) Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. The Lancet Respiratory Medicine.  Accessed March 2022 

MAT-GLB-2201308 04/2022